ISGLT2 in Patients Without DM With Acute MI

Inclusion Criteria :

• Participant must approved the informed consent.

• Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definitionof MI (Thygesen et al 2019).

• Evidence of impaired regional or global LV systolic function at any timepoint duringcurrent MI-related hospitalisation with Ejection Fraction<50%(established withechocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) orSymptoms of Acute heart failure without cardiogenic Shock.

• Hemodynamically stable (no episodes of symptomatic hypotension, or arrhythmia withhaemodynamic compromise in the last 24 hours).

Exclusion Criteria:

• Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission.

• Chronic symptomatic HF with a prior HHF within the last year and known reducedejection fraction (LVEF≤40 %), documented before the current MI hospitalization.

• Patients with cardiogenic shock who received vasoactive drugs during index.

• Hospitalization Severe (eGFR <20 mL/min/1.73 m2 by local laboratory), unstable orrapidly progressing renal disease at the time of randomization

• Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into thetrial.

• Active malignancy requiring treatment at the time of screening.

• Any non-CV condition, eg malignancy, with a life expectancy of less than one yearsbased on the investigator´s clinical judgement.

• Currently on treatment, or with an indication for treatment, with a sodium glucoseco-transporter 2 inhibitor (SGLT2-inhibitor)